ClinicalTrials.gg
RecruitingNCT07012642Updated Jun 10, 2025

Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema

An Early Phase 1 interventional study of GLP-1 Receptor Agonists in Lymphedema, sponsored by Advanced Reconstructive Surgery Alliance. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-10.

Sponsored by Advanced Reconstructive Surgery Alliance · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 168 studies in Lymphedema with a site in United States — 37 open to participants now, 45 under way, 1 of them phase 3. Lymphedema · United States.

Planned enrollment
27th of 122
110 · median 50
Started
2025
with 6 others
Phase 1
8 of 168
2 open now
Primary completion
2027-04
later than 17 of 44 live
Registered
162nd of 168
by date

Among the 168 studies in Lymphedema with a site in United States, this one is the 27th largest by planned enrollment of the 122 interventional ones that give a count, is one of 7 that started in 2025, is one of 8 in phase 1, reaches primary completion later than 17 of the 44 other live ones, and was the 162nd registered.

Lymphedema

529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.

Browse Lymphedema studies →

Open to participants now

37 of the 168 studies in Lymphedema with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 168 studies in Lymphedema with a site in United States, or all of them as a file.
02

Study summary

Lymphedema affects millions and currently lacks effective drug treatments, relying mainly on compression therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in managing obesity and diabetes, which can worsen lymphedema. Although anecdotal evidence suggests benefits of GLP-1 RAs for lymphedema patients, rigorous prospective studies are lacking. This study aims to evaluate the effectiveness of GLP-1 RAs in improving quality of life and clinical outcomes in lymphedema patients, thereby addressing a critical gap in literature and potentially offering a new treatment option.

Read the detailed description

Research Protocol: GLP-1Ras - Investigator-Initiated Study

Principal Investigator: Joseph Dayan, MD, MBA

Title: Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema

Background and Rationale

Introduction: Lymphedema is an incurable and relentless progressive disease marked by swelling of the upper or lower limb requiring life-long compression. Patients have a high risk of cellulitis and deteriorating quality of life. Lymphedema is a major public health problem with an estimated incidence in the United States of 5 million. There is no cure and no drug to treat this disease.

Literature Review: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now ubiquitous in the United States given their effectiveness in treating obesity and diabetes. Elevated BMI and insulin resistance have been widely reported to worsen lymphedema. Consequently, GLP-1 RAs may have a positive effect on lymphedema. Anecdotally we have observed patients with chronic lymphedema dramatically improve after taking GLP-1 receptor agonists but there is currently no prospective data available.

Rationale: Lymphedema affects millions and currently lacks effective drug treatments, relying mainly on compression therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in managing obesity and diabetes, which can worsen lymphedema. Although anecdotal evidence suggests benefits of GLP-1 RAs for lymphedema patients, rigorous prospective studies are lacking. This study aims to evaluate the effectiveness of GLP-1 RAs in improving quality of life and clinical outcomes in lymphedema patients, thereby addressing a critical gap in literature and potentially offering a new treatment option.

Objectives

Primary Objective: To evaluate the quality-of-life improvements following GLP-1 RA treatment, utilizing the Lymphedema Life Impact Scale (LLIS) as a measurement tool.

Secondary Objectives: To evaluate the efficacy of GLP-1 RAs in reducing limb volume, bioimpedance, compression use, and incidence of cellulitis.

Hypotheses

GLP-1 receptor agonists will improve quality of life and reduce limb volume in lymphedema patients.

Study Design

Type of Study: Prospective, Single arm study, off-label use of GLP-1 receptor agonists to treat upper or lower extremity lymphedema.

Duration: 24 Months

Study Setting: Conduct at an outpatient lymphedema clinic

Population: Adults with Upper and lower extremity Lymphedema, (ISL) stages II and II

Sample Size: 110 participants

Follow-up Visits: Baseline, 3 months, and 6 months post-treatment visit

Participants

Eligibility Criteria

Inclusion Criteria:

Adults 18 years or older with unilateral upper or lower extremity lymphedema Limb volume > 5% BMI => 23 Oncology clearance if there is a cancer history

Exclusion Criteria:

Moderate to severe venous insufficiency Actively using GLP-1 RAs Known intolerance or adverse effect to GLP-1 RAs Medical history or morbidity where GLP-1 RAs are contraindicated as per patient's primary care provider such as MEN syndrome or history of thyroid cancer

Methods

Data Collection:

Lymphedema Life Impact Scale score (validated patient-reported outcome metric) Limb volume Bioimpedance BMI Compression use Incidence of cellulitis

Interventions: GLP-1 RA treatment will be administered by the patient's primary provider for 6 months.

Outcome Measures

Primary Outcome:

Patient reported quality of life outcome (Lymphedema Life Impact Scale)

Secondary Outcomes:

Limb volume Bioimpedance BMI Incidence of cellulitis Compression use

Data Analysis Plan

Statistical Methods:

Utilize appropriate statistical tests, including a t-test with an effect size of 0.15 and a power of 0.95.

To adequately power this study, 74 participants are needed to complete a 6-month course of GLP-1 RA treatment and follow-up. Assuming a dropout rate of 30%, we plan to enroll 110 patients to meet this goal.

Software:

IBM SPSS for data analysis.

Handling Missing Data:

To address missing data, all instances will be documented, and efforts will be made to recover missing information. Multiple imputation techniques will be used to estimate missing values for continuous variables, such as limb volume and LLIS scores. Sensitivity analyses will be conducted to evaluate the impact of missing data on study outcomes, ensuring robustness and transparency in the study's findings.

Ethical Considerations

Informed Consent:

Participants will provide informed consent, understanding the study's scope and procedures.

Confidentiality:

Participant data will be kept confidential, adhering to ethical standards.

Approval:

Ethical approval will be obtained from a relevant ethics committee or institutional review board (IRB).

Study Timeline Estimated Start Date: April 9, 2025

Estimated Completion Date: April 9, 2027

Recruitment:

Recruit patients from internal lymphedema population Clinicaltrials.gov Patient referrals from other providers and social media

Budget and Funding

Budget:

No anticipated study costs. The study participation is voluntary

Funding Sources:

The project is currently not funded

Potential Risks and Benefits

Risks, benefits, and alternatives to GLP-1 RA treatment will be discussed with the patient in addition to the patient reviewing this consideration with their provider.

The most common adverse event from GLP-1 treatment is gastrointestinal intolerance such as nausea or vomiting (5% incidence).

Adverse events:

The site will begin to report AE/SAE after the patient signs the informed consent.

All serious adverse events (SAEs) will be documented and reported to the Institutional Review Board (IRB) within 24 hours of the patient site becoming aware.

Participant Discontinuation/ Withdrawal from the study:

Participants have the right to withdraw from the study at any time upon their request.

Dissemination Plan:

The results of the study will be submitted as a research manuscript for publication in a peer-reviewed journal either the New England Journal of Medicine or the Journal of the American Medical Association.

03

Conditions studied

  • Lymphedema

Browse trials for

Keywords

  • Efficacy of GLP-1 in lymphedema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults 18 years or older with unilateral upper or lower extremity lymphedema Limb volume > 5% => 23 Oncology clearance if there is a cancer history

Exclusion criteria

Exclusion Criteria:

Moderate to severe venous insufficiency Actively using GLP-1 RAs Known intolerance or adverse effect to GLP-1 RAs Medical history or morbidity where GLP-1 RAs are as per patient's primary care provider such as MEN syndrome or history of thyroid cancer.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Study arm

    Participants will received GLP-1 RAs for 6 months to study the effects on lymphedema.

    Drug: GLP-1 Receptor Agonists

Interventions

06

What researchers measure

Primary outcomes

  1. Patient reported quality of life outcome using LLIS

    Lymphedema Life Impact Scale

    Time frame: 6 months

Secondary outcomes

  1. Physiological improvement

    Limb volume Bioimpedance BMI Incidence of cellulitis Compression use

    Time frame: 6 months

07

Study locations

2 of 2 sites recruiting
  • River Center
    Red Bank, New Jersey 07701, United States
    Recruiting
  • 260 Old Hook Rd Suite 304
    Westwood, New Jersey 07675, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified study results.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: At the conclusion of the study (start date) For five years (end date)

Access criteria: All de-identified study documents will be available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2025
First posted
Jun 10, 2025
StartActual
Apr 9, 2025
Primary completionEst.
Apr 9, 2027
CompletionEst.
Apr 9, 2027
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07012642
Lead sponsor
Advanced Reconstructive Surgery Alliance
Responsible party
Joseph Dayan (Principal Investigator, Advanced Reconstructive Surgery Alliance) — Principal investigator
First posted
Jun 10, 2025
Start date
Apr 9, 2025
Primary completion
Apr 9, 2027 (estimated)
Completion
Apr 9, 2027 (estimated)
Last update
Jun 10, 2025

Study contacts

Giana Truax
Contact
gtruax@sycamoremm.com
866-266-2577
Saba Tasawar
Contact
stasawar@sycamoremm.com
732-741-0970

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLP-1 receptor agonists

Start the discussion